ID: MRFR/MED/5099-CR | October 2019 | Region: Global | 141 pages
The Global New-Born Screening Market is expected to register a CAGR of 13.33% to reach USD 1545.98 Million till 2025.
New-born screening involves using devices for screening new-born babies for possibilities of different types of diseases that are not apparent at the time of birth. The rising prevalence of new-born diseases has led to the growth of the new-born screening market in recent years. Factors such as government support along with new-born screening programs and increasing neonatal population contribute to the growth of the market. In addition to this, technological advancements related to new-born screening are expected to fuel the market growth. However, the unreliability of few new-born screening tests, and lack of proper healthcare infrastructure and trained professionals are likely to restrain the market growth over the forecast period.
The key factors responsible for driving the market growth are rising prevalence of diseases in new-born children, increasing neonatal population, increasing expenditure on the healthcare IT sector, and technological advancements. However, the lack of proper healthcare infrastructure and trained professionals is projected to curb the growth of the market.
The increasing technological advancements in the healthcare sector are considered to grow the market in the coming years.
New-born screening programs offer a lot of benefits which positively affects the market growth. Governments of different regions are taking up a lot of initiatives and raising awareness about new-born screening and its benefits. Various government and non-government organizations are actively focused on offering better fetal and maternal care options. For example, in June 2018, the American Society of Hematology (ASH) led a campaign to fight sickle cell disease in Africa and urged governments, particularly in Sub-Saharan Africa, to invest in the new-born screening of the disease.
Additionally, several governments are supporting manufacturers to develop new screening tests by relaxing their regulations for the manufacturing and marketing of the products. For instance, in February 2017, the US Food and Drug Administration (FDA) approved the marketing of the seeker system for the screening of four rare lysosomal storage disorders (LSDs) in new-born children. The seeker system is designed to detect diseases such as Fabry, Gaucher, Mucopolysaccharidosis Type I (MPS I), and Pompe. It is also the first new-born screening test allowed to be marketed by the FDA for these disorders. Moreover, the US government has programs such as Screening Quality Assurance Programs and Heritable Disorders Program at Health Resources and Service Administration (HRSA). Therefore, such initiatives and programs by the government as well as non-government organizations support market growth.
Global New-Born Screening Market Share, by Product, 2018 & 2025 (USD MILLION)
Source: MRFR Analysis
The Global New-Born Screening Market has been segmented into product, technology, test type, and end user.
The Global New-Born Screening Market by products has been segregated into instruments and reagents and assay kits. The instruments segment is expected to grow owing to the increasing awareness about new-born screening and subsequently increasing the number of new-born screening tests. Various reagent kits and instruments are used in new-born screening and diagnosis of diseases in the early phase.
The Global New-Born Screening Market by technology has been divided into tandem mass spectrometry, DNA assays, electrophoresis, pulse oximetry, immunoassays and enzymatic assays, and hearing screening technology. The tandem mass spectrometry segment is expected to grow owing to the advancement in technology and raising awareness about new-born disorders. Furthermore, the pulse oximetry is anticipated to be the fastest-growing segment in the global new-born screening market by technology.
The Global New-Born Screening Market, by test type, has been classified as dry blood spot test, critical congenital heart disease (CCHD) test, urine test, and hearing screening test. The dry blood spot test is likely to hold a significant share owing to the growing awareness about new-born screening and its benefits and increasing number of new-born diseases. The CCHD test is anticipated to be the fastest-growing segment due to technological advancements, growing cases of congenital disabilities, and increasing government initiatives for new-born screening. According to the report published by the Centers for Disease Control and Prevention, in 2018, the number of cases of congenital disabilities are increasing and affecting one in every 33 babies born in the US each year.
The global new-born screening market, by end user, has been categorized as hospitals, maternity and specialty clinics, diagnostic centers, and others. Hospitals are anticipated to grow owing to the increasing support from governments for research & development carried out by hospitals and medical institutes. Moreover, diagnostic centers are expected to be the fastest-growing segment owing to the increase in the outsourcing of diagnostic services.
Global New-Born Screening Market Share, 2018 (%)
Source: MRFR Analysis
The global new-born screening market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas are anticipated to hold a significant share in the global new-born screening market. The rising prevalence of congenital disorders in new-born children, increasing neonatal population, and government support are driving the growth of the market in this region. The new-born screening programs are strictly followed everywhere in North America. In the US, new-born screening policies are made by the federal government as well as the state government.
The Prominent Players in the global new-born screening market are SCIEX (US), PerkinElmer Inc. (US), Waters (US), Natus Medical Incorporated (US), Masimo Corporation (US), Agilent Technologies Inc. (US), Bio-Rad Laboratories, Inc. (US), Medtronic PLC (Ireland), GENERAL ELECTRIC (Boston), Trivitron Healthcare (India), ZenTech SA (Belgium), and Thermo Fisher Scientific Inc. (US).
Some of the key strategies followed by players operating in the Global New-Born Screening Market were innovation, product development, and acquisition & mergers.
PerkinElmer Inc. accounted for 45.6% of the global newborn screening market share in 2017. It is a market leader in the global new-born screening market. The company operates through business segments, namely, discovery and analytical solutions and diagnostics and provides consumables, informatics, instruments, OEM solutions, reagents, software, and training to customers. The company emphasizes on delivering top quality products with advanced technology. PerkinElmer Inc. is expanding its portfolio by acquiring other market players. For instance, in December 2017, the company acquired EuroIMMUN Medical laboratory diagnostics AG to expand its medical devices business.
Bio-Rad Laboratories, Inc. accounted for the second-largest market share of 14.2% in 2017. The company is one of the major players in the life sciences market and offers instruments, software, consumables, reagents, and content for life sciences research and the healthcare sector. The company offers products related to clinical diagnostics in the newborn screening market. The company has a strong presence in the Americas, Europe, and the Pacific Rim. Bio-rad has a strong distribution network in all major markets. Strategic partnerships, collaborations, and new product launches are playing an essential role in the development of the company.
Natus Medical Incorporated operates in segments, including neurology, newborn care, and otometrics. The company accounted for 13.6% of the total market share in 2017. It offers medical equipment, software, and services for the diagnosis, monitoring, and treatment of diseases. Natus is a market leader in hearing screening devices and the technology market. It holds approximately 70% market share of the newborn hearing screening test market. The company is launching new products in emerging economies to capture untapped markets. America and Europe are important markets for the company, and it generates more than 50% of its revenue from the US.
Global New-Born Screening Market, by Product
Reagents and Assay Kits
Global New-Born Screening Market, by Technology
Tandem Mass Spectrometry
Immunoassays and Enzymatic Assays
Hearing Screening Technology
Global New-Born Screening Market, by Test Type
Dry Blood Spot Test
Hearing Screening Test
Critical Congenital Heart Disease (CCHD) Test
Global New-Born Screening Market, by End User
Maternity and Specialty Clinics
Global New-Born Screening Market, by Region
Rest of Western Europe
Rest of Asia-Pacific
Middle East & Africa
Available Additional Customizations
Company Profiles of Other Key Players
MP Biomedicals LLC
Medical device companies
Contract research manufacturing organizations
Research & development organizations
Frequently Asked Questions (FAQ) :
The global new-born screening market is projected to reach a valuation of USD 1545.98 MN by 2025.
The global new-born screening market is projected to grow at approximately 13.33% CAGR during forecast period (2019-2025).
Increasing expenditures in the healthcare IT sector.
North America holds the largest share in the global new-born screening market, followed by Europe and the Asia Pacific, respectively.
PerkinElmer Inc. (US), SCIEX (US), Waters (US), Masimo Corporation (US), Natus Medical Incorporated (US), Agilent Technologies Inc. (US), Medtronic PLC (Ireland), Bio-Rad Laboratories, Inc. (US), GENERAL ELECTRIC (Boston), ZenTech SA (Belgium), Trivitron Healthcare (India), and Thermo Fisher Scientific Inc. (US), are some of the major players operating in the new-born screening market.